Is NTLA or TRIB more undervalued in 2026?

CirclFi compares Intellia Therapeutics, Inc. (NTLA) and Trinity Biotech plc (TRIB) using 13 institutional-grade valuation models. NTLA has a Quality of Company score of 6.5/10 while TRIB scores 4.0/10.

Which is a better buy — NTLA or TRIB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NTLA and TRIB valuations compare?

NTLA at $14.07 and TRIB at $0.70 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NTLA vs TRIB Valuation Comparison 2026 — Intrinsic Value Analysis

NTLA

In Vitro & In Vivo Diagnostic Substances

Intellia Therapeutics, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$14.07

Last close

Models

9/13

Active

TRIB

In Vitro & In Vivo Diagnostic Substances

Trinity Biotech plc

Quality

4.0

out of 10

Value Trap

SAFE

Price

$0.70

Last close

Models

5/13

Active

Model-by-Model Comparison

Model	Type	NTLA Fair Value	NTLA Upside	TRIB Fair Value	TRIB Upside
Bayesian DCF	Intrinsic	$3.57	-74.7%	$3.89	+453.3%
Earnings Power Value	Intrinsic	—	—	$0.40	-33.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.55	-95.5%	$0.07	-90.5%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NTLA vs TRIB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NTLA vs TRIB — Which Stock Is More Undervalued?

NTLA scores higher with a 6.5/10 quality rating vs TRIB's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Intellia Therapeutics, Inc. (NTLA) and Trinity Biotech plc (TRIB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NTLA currently trades at $14.07 with a QOC of 6.5/10, while TRIB trades at $0.70 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).